Background/ Aim: Silymarin is a polyphenolic compound with anti-hepatotoxic activity. It has low oral bioavailability due to its poor aqueous solubility. Thus enhancement of its dissolution may lead to a better bioavailability. The objective of the presented study was to prepare fast dissolving enriched silymarin preparation via the preparation of enriched silymarin as solid dispersion and compare it with Legalon capsules in chronic HCV patients in a clinical study. Method: Enriched silymarin solid dispersion was prepared in sufficient amount. A clinical study was conducted including 24 patients. The patients were divided into two groups; each group had 12 patients. One group received the solid dispersion. The second group received Legalon capsules. Patients received capsules 3 times daily for 12 weeks. All these patients had been subjected to full medical history, abdominal ultrasonography, laboratory investigations and quality of life assessment at baseline and after treatment. Results: Solid dispersion had significantly faster dissolution rate. It is effective in reducing AST, ALT, total bilirubin, improving prothrombin concentration, prothrombin time and quality of life. Conclusion: Silymarin solid dispersion is a promising preparation. Large scale and longer duration may be required to ascertain its effects.
INTRODUCTION
HCV is known as the sole member of genus Hepacivirus belonging to a group of genetically diverse RNA viruses of family Flaviviridae (Reed and Rice 2000) . In 1989 HCV was cloned using a molecular biological approach where many other techniques had failed (Choo, Kuo, et al. 1989 ). According to recent estimates, more than 185 million people around the world have been infected with HCV, of whom 350 000 die each year (Mohd Hanafiah, Groeger, et al. 2013) . The high incidence of HCV makes it one of the greatest health threats facing the world today. Fifty to eighty % cases of chronic hepatitis with viral persistence being at risk to develop liver inflammation, fibrosis, cirrhosis and HCC (Timm and Roggendorf 2007) . HCV is endemic in Egypt. The genotype distribution in Egypt is mainly genotype 4 (HCV G4) (Abdel-Aziz, Habib, et al. 2000) . The recently released Egyptian Demographic Health Survey [EDHS] tested a representative sample of the entire country for HCV antibody and revealed that the overall anti-HCV prevalence was 14.7% and viremia was 9.8% (Shaker, Sadik, et al. 2012) . About 80% of those exposed to the virus develop a chronic infection (Nelson, Mathers, et al. 2011 ). The course of chronic HCV infection is prolonged and usually, progresses with only a few symptoms or signs for the first 20 years after the disease is contracted. Moderate to severe hepatitis will develop in these patients. Inflammation and hepatic cell necrosis often lead to fibrosis and cirrhosis (Poynard, Bedossa, et al. 1997) . Worldwide hepatitis C is the cause of 27% of cirrhosis cases which developed over 30 years and 25% of hepatocellular carcinoma (Alter 2007) . Interferon had been the backbone of therapy for hepatitis C virus (HCV) infection for over 20 years. The most effective antiviral therapy until the last year consisted of subcutaneous injections of long-acting pegylated interferon-α 2a or 2b (PEG-IFN) combined with oral treatment with ribavirin (RBV). Advances in the understanding of the HCV lifecycle have led to the development of numerous highly effective, welltolerated oral direct-acting antivirals (DAAs) (Feld 2014) . The disadvantages of the antiviral regimen of pegylated interferon and ribavirin is difficult to tolerate (Fried 2002) , expensive, requires up to 48 weeks of treatment, and cures only 40-60% of a very highly selected group of patients (McHutchison, Gordon, et al. 1998) . DAAs therapy has the disadvantage that the impending arrival of multiple DAA regimens may drive the cost of therapy to become prohibitively expensive, and therefore not affordable to people in resource-poor settings (Feld 2014) . Herbal supplements are frequently used in chronic HCV infection. Silymarin, the active component of the milk thistle plant is the most commonly used herbal supplement for liver disease (Seeff, Lindsay, et al. 2001) . The primary active constituent of milk thistle is silymarin, which is composed of four isomers: silybin, isosilybin, silychristin and silydianin (Lee and Liu 2003) . Most of the Silymarinhepatoprotective properties are attributed to silybin (also called silibinin) which is the main constituent (60-70%) (Wellington and Jarvis 2001) . The biological activity of silymarin is limited after oral administration due to its poor solubility in water resulting in poor absorption and low bioavailability (Li, Hu, et al. 2003) .Thus enhancement of solubility may lead to increase the absorption rate and better bioavailability. Solid dispersions are one of the most successful strategies to improve drug release of poorly soluble drugs. These can be defined as molecular mixtures of poorly water soluble drugs in hydrophilic carriers (Vasconcelos, Sarmento, et al. 2007 ).
METHODS
Silymarin-polyvinyl pyrrolidone(PVP) solid dispersion was prepared using rotary evaporator in (1:1) drug: polymer weight ratio.Silibinin-polyvinyl pyrrolidone (PVP) solid dispersion was prepared in the same manner. Capsules were prepared to contain amount equivalent to 100 mg silymarin and 40 mg silybin as solid dispersion (enriched capsules). Capsules of commercial Legalon were supplied containing 140 mg silymarin. All capsules were taken three times daily for three months. The study included 24 patients with chronic HCV infection on the basis of HCV-antibodies by third generation ELISA, PCR result and liver biopsy after exclusion of patients who had co-infection with hepatitis B virus (HBV) or human immune deficiency virus (HIV), pregnant and lactating women, patients with decompensated liver disease and patients who received treatment with antiviral agents or IFN therapy during 6 months before study. They were selected from patients attending the outpatient clinic of tropical medicine department -El Minia University Hospital. All these patients had been subjected to full medical history, abdominal ultrasonography, quality of life assessment using chronic liver disease questionnaire (CLDQ), measurement of ALT, AST, bilirubin, albumin, total protein, prothrombin time, prothrombin concentration at baseline and after follow-up for 3 months.
The patients were classified into two groups: -Group I included 12 patients who received the prepared enriched capsules (containing amount equivalent to 100 mg silymarin and 40 mg silybin as solid dispersion). -Group II included 12 patients who received Legalon capsules (containing 140 mg silymarin).
Patients received capsules 3 times daily for 3 months.
RESULTS
It was found that enriched solid dispersion had higher dissolution rate than its corresponding physical mixture and Silymarin (figure 1). In the clinical study, statistical analysis was done using software program SPSS version 11; Quantitative data were presented as mean and standard deviation while qualitative data were presented as frequency distribution Chi-square, Mann-Whitney test was used to test the significant difference between the groups. Wilcoxon was used to testing the comparison between before and after in each studied groups. The results are significant at P value less than 0.05. The main results of the study are illustrated as following:
It was found that there was a non-significant difference between the two groups before treatment (Table 1) . Figure  2&3 ). Concerning to quality of life assessment, after treatment, it was found that:
Patients received enriched silymarin solid dispersion capsules (Group I); there was a highly significant improvement in abdominal symptoms (AS), fatigue (FA), systemic symptoms (SS) activity (AC) emotional function (EF) and worry (WO) (P value= 0.001, 0.001, 0.001, 0.001, 0.001, 0.001) respectively. While patients received Legalon capsules (Group II), there was slight change in abdominal symptoms (AS), fatigue (FA), systemic symptoms (SS) activity (AC)and non-significant improvement in emotional function (EF) and worry (WO) (P value= 0.5, 0.2, 0.2, 0.1, 0.06, 0.2) respectively (Table 3, figure 4&5 ). 
DISCUSSION
It is important to mention that this is the first clinical study on Silymarin solid dispersion formula in which water solubility of silymarin was improved significantly which in turn improve its bioavailability. Oral drug delivery is the simplest and easiest way of administering drugs (Youn, Jung, et al. 2006 ). Because of the greater stability, smaller bulk, accurate dosage and easy production. Capsules were prepared in sufficient amount for clinical study. The mechanism of action of silymarin and its role in the treatment of viral hepatitis will be discussed below. Silymarin is reported to have antioxidant activity (Parveen, Baboota, et al. 2011) , by increasing superoxide dismutase activity in erythrocytes and lymphocytes (Varga, Czompa, et al. 2001) .It is also reported to stabilize hepatocyte membrane structure, thereby preventing toxins from entering the cell through enterohepatic recirculation. It promotes liver regeneration by stimulating nuclear polymerase A (Leng-Peschlow. 1996) and stimulation of ribosomal RNA polymerase and subsequent protein synthesis (Dixit, Baboota, et al. 2007 ). Silybin selectively inhibits leukotriene formation by Kupffer cells (Dehmlow, Erhard, et al. 1996) . In part 1 the results concerning to Group I was in agreement with Buzzelli et al. study were 20 patients with chronic hepatitis B, C, or both were randomized to receive a silybin complex or placebo. Compared with baseline and the group receiving placebo, the Silymarin group had statistically significant decreases in transaminases and GGT (Buzzelli, Moscarella, et al. 1993 ). This also was in agreement with A double-blind, randomized, crossover study involving 10 patients with hepatitis C not responsive to interferon a2b found a significant decrease in transaminases in those treated with silybin (silipide 260 mg) daily for 2 months compared with placebo (Buzzelli, Moscarella, et al. 1994 ). This also was in agreement with Shindo et al. who concluded that silymarin treatment resulted in a statistically significant decrease in transaminases in four studies compared with baseline and in one compared with placebo in patients with chronic viral hepatitis (Shindo, Hamada, et al. 2001) . If silymarin does indeed lower ALT levels and help achieve a biochemical response, it may also act synergistically with interferon to increase the rates of sustained virological response, but this hypothesis has yet to be clinically investigated (Mayer, Myers, et al. 2005 ).
Concerning to Group II, the result was in agreement with Abdel-Hamid et al. who studied Legalon on a large scale (number of patients =140). They received the recommended dose of silymarin for 12 months. In this study, there was also no effect for Legalon on liver function tests (Abdel-Hamid, Labeeb, et al. 2004 ). In part 2, at baseline evaluation, it was found that our patients had reduced health-related quality of life (HRQOL). It agrees with the study which concluded that patients with hepatitis C infection have a reduced (HRQOL) (Foster, Goldin, et al. 1998 ).
The result in Group I was in agreement with a survey by Flora et al., which concluded that more than 50% of patients taking silymarin reported subjective improvement of symptoms, but the data was insufficient to determine whether or not this correlated with improved liver biochemistry (Flora, Hahn, et al. 1998 
CONCLUSION
Silymarin solid dispersion is a promising preparation. It is effective in reducing AST, ALT, total bilirubin, improving prothrombin concentration, prothrombin time and quality of life. Large scale and longer duration may be required for enriched silymarin solid dispersion to ascertain its effects.
